INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,618,850 | +8.6% | 195,000 | 0.0% | 0.10% | -1.0% |
| Q4 2022 | $2,412,150 | -56.2% | 195,000 | -50.6% | 0.10% | -57.4% |
| Q3 2022 | $5,510,000 | +1.0% | 395,000 | 0.0% | 0.24% | +8.4% |
| Q2 2022 | $5,455,000 | -25.5% | 395,000 | -12.2% | 0.22% | +3.2% |
| Q1 2022 | $7,322,000 | -0.1% | 450,000 | 0.0% | 0.22% | +17.8% |
| Q4 2021 | $7,331,000 | -25.2% | 450,000 | -31.8% | 0.18% | -28.6% |
| Q3 2021 | $9,801,000 | +46.5% | 660,000 | +97.0% | 0.26% | +46.3% |
| Q2 2021 | $6,690,000 | -13.5% | 335,000 | 0.0% | 0.18% | -14.5% |
| Q1 2021 | $7,732,000 | -6.6% | 335,000 | 0.0% | 0.21% | -4.2% |
| Q4 2020 | $8,275,000 | +32.2% | 335,000 | +121.9% | 0.22% | +16.8% |
| Q3 2020 | $6,260,000 | -13.5% | 151,000 | 0.0% | 0.18% | -21.9% |
| Q2 2020 | $7,234,000 | -23.9% | 151,000 | 0.0% | 0.24% | -37.6% |
| Q1 2020 | $9,507,000 | -54.1% | 151,000 | -9.6% | 0.38% | -46.8% |
| Q4 2019 | $20,695,000 | +58.3% | 167,000 | -15.2% | 0.71% | +48.1% |
| Q3 2019 | $13,073,000 | -16.6% | 197,000 | 0.0% | 0.48% | -18.0% |
| Q2 2019 | $15,675,000 | -21.9% | 197,000 | +9.4% | 0.59% | -28.9% |
| Q1 2019 | $20,070,000 | +172.8% | 180,000 | +146.6% | 0.83% | +124.7% |
| Q4 2018 | $7,358,000 | -22.4% | 73,000 | -2.7% | 0.37% | -9.4% |
| Q3 2018 | $9,477,000 | +41.2% | 75,000 | -6.2% | 0.41% | +31.4% |
| Q2 2018 | $6,713,000 | +36.4% | 80,000 | 0.0% | 0.31% | +31.5% |
| Q1 2018 | $4,922,000 | +27.6% | 80,000 | +21.2% | 0.24% | +29.1% |
| Q4 2017 | $3,856,000 | +0.7% | 66,000 | 0.0% | 0.18% | +0.6% |
| Q3 2017 | $3,831,000 | -39.2% | 66,000 | +26.9% | 0.18% | -41.4% |
| Q2 2017 | $6,296,000 | +7.1% | 52,000 | 0.0% | 0.31% | +3.0% |
| Q1 2017 | $5,881,000 | +17.7% | 52,000 | +13.0% | 0.30% | +11.5% |
| Q4 2016 | $4,998,000 | -34.0% | 46,000 | 0.0% | 0.27% | -32.9% |
| Q3 2016 | $7,571,000 | +36.0% | 46,000 | +17.9% | 0.40% | +31.5% |
| Q2 2016 | $5,565,000 | +39.7% | 39,000 | +25.8% | 0.30% | +37.4% |
| Q1 2016 | $3,983,000 | -8.0% | 31,000 | +6.9% | 0.22% | -6.3% |
| Q4 2015 | $4,331,000 | -3.3% | 29,000 | +7.4% | 0.24% | -7.1% |
| Q3 2015 | $4,478,000 | -15.7% | 27,000 | +22.7% | 0.26% | -8.6% |
| Q2 2015 | $5,310,000 | +169.0% | 22,000 | +214.3% | 0.28% | +173.5% |
| Q1 2015 | $1,974,000 | – | 7,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |